Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Cessatech

13,46

 

DKK

 

+2,28 %

Mindre end 1K følgere

CESSA

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
Sammenligne
+2,28%
+6,49%
+13,59%
+14,07%
+3,54%
+119,22%
+109,21%
-
+24,81%

Cessatech er aktiv i medicinalindustrien. Virksomheden har specialiseret sig i forskning og udvikling af smertestillende næsespray, der yderligere bruges til behandling af akutte smertetilstande hos børn. Udover hovedforretningen tilbydes også tilknyttede supplerende tjenester og relaterede produkter. Forretningen drives globalt med den største tilstedeværelse på det nordiske marked. Hovedkontoret ligger i København.

Læs mere
Markedsværdi
250,2 mio. DKK
Aktieomsætning
186,18 t DKK
Omsætning
2,49 mio.
EBIT %
-765,06 %
P/E
-
Udbytteafkast, %
-
Finanskalender
21.8
2025

Delårsrapport Q2'25

13.11
2025

Delårsrapport Q3'25

Alle
Analyse
Selskabsmeddelelser
ViserAlle indholdstyper
Selskabsmeddelelse28.5.2025, 20.30

Cessatech has carried out a directed share issue of approximately DKK 14.8 million to strengthen its financial position ahead of U.S. commercial launch

Cessatech
Selskabsmeddelelse28.5.2025, 15.30

Cessatech announces intention to carry out a directed share issue ahead of U.S. commercial launch

Cessatech
Selskabsmeddelelse28.5.2025, 15.15

Cessatech announces positive top-line results from its final CT001 Study 0202

Cessatech

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Selskabsmeddelelse15.5.2025, 06.30

Cessatech: First Quarter Report Q1-2025

Cessatech
Selskabsmeddelelse30.4.2025, 13.45

Cessatech announces that recruitment has completed in the Paediatric Study 0202, and now the EMA submission process can be initiated for CT001

Cessatech
Selskabsmeddelelse28.3.2025, 10.30

Minutes from the Annual General Meeting in Cessatech A/S

Cessatech
Selskabsmeddelelse12.3.2025, 07.30

Cessatech: Annual General Meeting - 28 March 2025

Cessatech
Selskabsmeddelelse28.2.2025, 07.30

Cessatech A/S publishes Annual Report for the fiscal year 2024

Cessatech
Selskabsmeddelelse4.2.2025, 10.30

Cessatech receives positive Notified Body opinion under MDR for CT001

Cessatech
Selskabsmeddelelse23.12.2024, 11.00

Cessatech updates the milestones for the coming year

Cessatech
Selskabsmeddelelse13.11.2024, 12.00

Cessatech: Third Quarter Report Q3-2024

Cessatech
Selskabsmeddelelse16.10.2024, 08.00

Cessatech announces that recruitment has today reached the halfway point for patient recruitment with 75 included patients in the Paediatric Study 0202

Cessatech
Selskabsmeddelelse2.9.2024, 08.00

Cessatech and Proveca partnership - Q&A

Cessatech
Selskabsmeddelelse26.8.2024, 06.30

Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001

Cessatech
Selskabsmeddelelse21.8.2024, 06.30

Cessatech: Second Quarter Report Q2-2024

Cessatech
Selskabsmeddelelse12.8.2024, 09.50

Cessatech extends its undrawn Loan Facility Agreement to DKK 10 million to support the forthcoming US launch of its lead program CT001

Cessatech
Selskabsmeddelelse2.8.2024, 13.00

Key Cessatech priorities for the rest of the year

Cessatech
Selskabsmeddelelse26.7.2024, 14.00

Cessatech: Grant of incentive warrants to Employees, CEO and the Board of Directors

Cessatech
Selskabsmeddelelse5.7.2024, 12.36

Cessatech announces changes to the Board of Directors

Cessatech
Selskabsmeddelelse5.7.2024, 12.31

Cessatech: Minutes of the Extraordinary General Meeting - 5 July 2024

Cessatech
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team